PMA P110012S022

Device
Vysis ALK Break Apart FISH Probe Kit
Applicant
Abbott Molecular, Inc.
PMA number
P110012
Supplement
S022
Product code
OWE
Decision date
2025-08-05
Classification
Pathology
Generic name
Fluorescence in situ hybridization, anaplastic lymphoma kinase, gene rearrangement
Approval order statement
Approval of the expansion of the Indications for Use for the Vysis ALK Break Apart FISH Probe Kit to include an indication for ENSACOVE® (ensartinib). The device, as modified, will be marketed under the trade name Vysis ALK Break Apart FISH Probe Kit and is indicated for:INTENDED USE The Vysis ALK Break Apart FISH Probe Kit is a qualitative test to detect rearrangements involving the ALK gene via fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded (FFPE) tissue specimens from non-small cell lung cancer (NSCLC) patients.INDICATION FOR USE The Vysis ALK Break Apart FISH Probe Kit is indicated as an aid in identifying patients eligible for treatment with XALKORI® (crizotinib), ALUNBRIG® (brigatinib), and ENSACOVE® (ensartinib) in accordance with the approved therapeutic product labeling.

Current openFDA PMA Record#

Device
Vysis ALK Break Apart FISH Probe Kit
Applicant
Abbott Molecular, Inc.
PMA number
P110012
Supplement
S022
Product code
OWE
Generic name
Fluorescence in situ hybridization, anaplastic lymphoma kinase, gene rearrangement
Decision date
2025-08-05
Decision code
APPR
Date received
2024-02-05
Supplement type
Normal 180 Day Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Approval order statement
Approval of the expansion of the Indications for Use for the Vysis ALK Break Apart FISH Probe Kit to include an indication for ENSACOVE® (ensartinib). The device, as modified, will be marketed under the trade name Vysis ALK Break Apart FISH Probe Kit and is indicated for:INTENDED USE The Vysis ALK Break Apart FISH Probe Kit is a qualitative test to detect rearrangements involving the ALK gene via fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded (FFPE) tissue specimens from non-small cell lung cancer (NSCLC) patients.INDICATION FOR USE The Vysis ALK Break Apart FISH Probe Kit is indicated as an aid in identifying patients eligible for treatment with XALKORI® (crizotinib), ALUNBRIG® (brigatinib), and ENSACOVE® (ensartinib) in accordance with the approved therapeutic product labeling.